絞り込み

17703

広告

トランプ氏、米企業のTikTok買収容認 期限区切り (朝日新聞)

スマートフォンに表示されたTikTok(ティックトック)アプリのアイコン(画像を加工しています) [PR] トランプ米大統領は3日、中国企業バイトダンス傘下の動...

  1. [企業] AbbVie、Amgen、武田...
  2. 岩石風化による年輪から形成時間の読み取り...
  3. [企業] MorphoSys/Incyt...
  4. 新型コロナ、なぜこんなに「無症状」が多い...

ニュース一覧

Successful treatment of an elderly patient with an uncommon L861Q epidermal growth factor receptor mutation with low-dose afatinib: A case report.

著者 Iida Y , Kumasawa F , Shimizu T , Shintani Y , Takahashi N , Gon Y
Thorac Cancer.2019 Nov 28 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (41view , 0users)

Full Text Sources

Miscellaneous

Research Materials

There are limited data on the clinical efficiency of afatinib in non-small cell lung cancer (NSCLC) patients with uncommon epidermal growth factor receptor (EGFR) mutations. Moreover, the efficacy and safety of afatinib in elderly patients with these mutations has not been established. Here, we describe a case of successful treatment of a patient aged >80 years with lung adenocarcinoma positive for the uncommon EGFR L861Q mutation with low-dose afatinib. An 83-year-old woman presented with cough and dyspnea. A chest computed tomography (CT) scan revealed tumors in the left upper lobe, left pleural effusion, and multiple lung metastases in both lungs. The patient was diagnosed with lung adenocarcinoma with an EGFR L861Q mutation based on cytological findings. The patient received 30 mg/day of afatinib and experienced no severe adverse events. Two weeks later, partial response was observed based on a CT scan. The results of the present case support the effectiveness and safety of low-dose afatinib in elderly patients with EGFR L861Q mutation-positive NSCLC.
PMID: 31779047 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード